Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2) Article (Faculty180)

cited authors

  • Stechschulte, L A; Ge, Chunxi; Hinds, Terry D; Sanchez, Edwin R; Franceschi, Renny T; Lecka-Czernik, Beata

authors

publication date

  • 2018

published in

start page

  • 8314

volume

  • 293